Urokinase-type Plasminogen Activator-induced Mouse Back Pain Model
1 septembre 2023
2.1K vues
Methods for simple, rapid induction of a back pain model in mice are provided here using an intraligament injection of urinary plasminogen activator.
Overview
This protocol outlines a non-invasive method to induce chronic back pain in mice for up to 10 weeks, which can be performed quickly and reliably with minimal training. The technique focuses on recognizing the difference between injecting ligament and muscle.
Key Study Components
Area of Science
- Neuroscience
- Animal Models
- Pain Research
Background
- Chronic back pain is a significant health issue.
- Animal models are essential for studying pain mechanisms.
- Reliable methods for inducing pain in mice are needed for research.
- This protocol aims to provide a simple approach for researchers.
Purpose of Study
- To develop a rapid method for inducing back pain in mice.
- To facilitate research on chronic pain mechanisms.
- To minimize the training required for researchers.
Methods Used
- Intraligament injection of urinary plasminogen activator.
- Use of a sterile flat surface for mouse placement.
- Heating pad recovery station for post-injection care.
- Technique for identifying correct injection site through resistance.
Main Results
- The method reliably induces chronic back pain in mice.
- Minimal training is required for successful implementation.
- Injection technique can be mastered with practice.
- Results can be observed for up to 10 weeks.
Conclusions
- This protocol provides a straightforward approach for pain induction.
- It supports ongoing research into chronic pain mechanisms.
- Future studies can build upon this method for various applications.
Frequently Asked Questions
What is the main advantage of this method?
The method is simple and requires minimal training, making it accessible for researchers.
How long does the induced pain last?
The induced chronic back pain can last for up to 10 weeks.
What is the key to successful injection?
Recognizing the resistance when injecting ligament is crucial for success.
Is this method invasive?
No, it is a non-invasive method for inducing pain in mice.
What equipment is needed for this procedure?
A sterile flat surface, a heating pad, and the injection materials are required.
Can this method be used for other types of pain research?
Yes, it can be adapted for various pain research applications.
Executive Industry Relevance
Persistent lower back pain remains a major translational challenge in pain therapeutics, with limited preclinical models that accurately reflect chronicity and behavioral comorbidities. The urokinase-type plasminogen activator-induced mouse model enables rapid, reproducible induction of long-lasting back pain, supporting mechanistic de-risking and target validation for novel analgesic candidates. This model addresses a critical inflection point in the pain drug discovery pipeline by providing a robust platform for quantitative, cross-functional evaluation of therapeutic hypotheses.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of pain pathway mechanisms and functional target validation in a disease-relevant context.
- Supports biological de-risking by modeling persistent pain and associated behavioral phenotypes.
- Facilitates predictive confidence in target selection through quantifiable, reproducible endpoints.
Screening & Assay Development
- Provides a validated in vivo system for screening analgesic compounds against chronic pain phenotypes.
- Standardizes behavioral assays for mechanical, thermal, and cold hypersensitivity, as well as anxiety and depression-like measures.
- Enables reproducible, quantitative outputs for compound evaluation and assay platform reuse.
Translational & Preclinical Research
- Aligns with disease-relevant endpoints, including gait disturbance and affective comorbidities, for translational biomarker development.
- Supports continuity from early discovery through preclinical validation by modeling persistent pain states.
- Provides risk-adjusted advancement criteria for candidate therapeutics targeting chronic pain.
Pipeline & Workflow Integration
This model integrates into the discovery-to-preclinical continuum, bridging early mechanistic studies and lead identification with translationally relevant behavioral outputs.
- Discovery Biology: Supports hypothesis testing and pathway clarification for pain mechanisms using quantifiable behavioral endpoints.
- Screening: Delivers assay-ready, reproducible outputs for compound screening and comparative analysis.
- Analytics: Provides mechanical withdrawal thresholds, latency measurements, and behavioral scores for robust statistical analysis.
- Translational Research: Models clinically relevant pain and comorbidities, supporting biomarker alignment and preclinical continuity.
- Enterprise Reuse: Offers a standardized, scalable platform for repeated use across pain research programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in pain target validation.
- Operational Value: Enables standardized, reproducible, and scalable induction of persistent pain phenotypes.
- Strategic Value: Improves go/no-go decision-making and capital efficiency by providing robust preclinical data.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of analgesic candidates.
Implementation Considerations
- Requires expertise in precise in vivo injection and behavioral assay execution.
- Needs access to specialized instrumentation for behavioral and sensory testing.
- Demands cross-team standardization of assay protocols and data analysis.
- Adaptable across mouse strains but may require optimization for specific genetic backgrounds.
- Limitations include the need for careful injection technique to avoid off-target effects.
Biopharma FAQs
Why does null hypothesis testing matter for Von Frey threshold analysis?
Null hypothesis testing in Von Frey threshold analysis ensures that observed differences in mechanical sensitivity are statistically significant, supporting robust target validation and reducing false positives in pain research pipelines.
How does independent variable isolation in urokinase injection support discovery?
Isolating the urokinase injection as the independent variable allows clear attribution of behavioral and sensory changes to the intervention, strengthening mechanistic insights and enabling confident progression in early discovery.
What do quantitative dependent variable measurements in the Hargreaves and Cold Plate tests enable?
Quantitative measurements from Hargreaves and Cold Plate tests provide objective, reproducible endpoints for thermal and cold hypersensitivity, facilitating cross-study comparisons and data-driven compound evaluation.
Why are replication requirements critical for cross-functional behavioral assay collaboration?
Replication ensures that behavioral assay results are consistent and reliable across teams, supporting collaborative decision-making and reducing variability in multi-site or multi-program pain research efforts.
What statistical analysis capabilities are required before implementing the sucrose splash depression test?
Robust statistical analysis, including curve fitting and threshold determination, is essential for interpreting grooming frequency and latency data, ensuring that behavioral changes are meaningful and actionable for therapeutic evaluation.
